France · Delayed Price · Currency is EUR Euroapi Earnings Call Transcripts
Fiscal Year 2025
-
Net sales declined 7% to EUR 848 million in 2025, with core EBITDA up 31% to EUR 66.2 million and a margin of 7.8%. Portfolio rationalization and cost discipline drove improved profitability, but 2026 sales are expected to fall 10% amid ongoing market and competitive pressures.
-
Net sales declined 8.2% year-over-year to EUR 412 million, with core EBITDA margin at 9.6% and a net loss of EUR 28.5 million. H2 is expected to strengthen, driven by HP API sales, CMO activity, and vitamin B12 recovery, while cost discipline and strategic investments continue.
-
The AGM reviewed a challenging 2024 marked by lower revenues, a net loss, and major restructuring under the Focus 27 plan. All resolutions were approved, including governance and compensation changes, with management emphasizing restored profitability, diversification, and ESG progress.
Fiscal Year 2024
-
Net sales fell 10% to EUR 911.9 million in 2024, with core EBITDA margin at 5.5% and a net loss of EUR 130.6 million. Focus 27 plan advanced, with 2025 guidance for steady sales and improved 7-9% EBITDA margin, supported by ongoing cost and portfolio optimization.
-
H1 2024 saw a 9.6% drop in net sales and a 23.8% decline in core EBITDA, mainly due to lower Sanofi volumes and Brindisi suspension, but gross margin improved. FOCUS-27 transformation is progressing, with restructuring and financing on track, and full-year guidance confirmed despite ongoing challenges.
-
FOCUS-27 will transform operations by discontinuing loss-making APIs, divesting two sites, and focusing on profitable products and CDMO growth. 2024 guidance anticipates lower sales and EBITDA, with significant restructuring and capital investments planned.